{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:12:55Z","timestamp":1775841175076,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s10549-019-05178-z","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T15:14:07Z","timestamp":1556118847000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-7547","authenticated-orcid":false,"given":"Maysa M.","family":"Abu-Khalaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Safonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Hatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"issue":"16","key":"5178_CR1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"issue":"31","key":"5178_CR2","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2\u2013overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811\u20137819. https:\/\/doi.org\/10.1200\/JCO.2005.02.4091","journal-title":"J Clin Oncol"},{"issue":"2","key":"5178_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","volume":"109","author":"E Bria","year":"2008","unstructured":"Bria E, Cuppone F, Fornier M et al (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109(2):231\u2013239. https:\/\/doi.org\/10.1007\/s10549-007-9663-z","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"5178_CR4","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"SD Russell","year":"2010","unstructured":"Russell SD, Blackwell KL, Lawrence J et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the North Central cancer treatment group N9831 clinical trials. J Clin Oncol 28(21):3416\u20133421. https:\/\/doi.org\/10.1200\/JCO.2009.23.6950","journal-title":"J Clin Oncol"},{"issue":"21","key":"5178_CR5","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E et al (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol 28(21):3422\u20133428. https:\/\/doi.org\/10.1200\/JCO.2009.26.0463","journal-title":"J Clin Oncol"},{"issue":"16","key":"5178_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"issue":"8","key":"5178_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or Without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231\u20131238. https:\/\/doi.org\/10.1200\/JCO.2007.13.5467","journal-title":"J Clin Oncol"},{"issue":"8","key":"5178_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 27(8):1177\u20131183. https:\/\/doi.org\/10.1200\/JCO.2008.18.4028","journal-title":"J Clin Oncol"},{"issue":"9555","key":"5178_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(07)60028-2","journal-title":"Lancet"},{"issue":"14","key":"5178_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"issue":"25","key":"5178_CR11","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2\u2013positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29(25):3366\u20133373. https:\/\/doi.org\/10.1200\/JCO.2011.35.0868","journal-title":"J Clin Oncol"},{"issue":"34","key":"5178_CR12","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29(34):4491\u20134497. https:\/\/doi.org\/10.1200\/JCO.2011.36.7045","journal-title":"J Clin Oncol"},{"issue":"12","key":"5178_CR13","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/annonc\/mds127","volume":"23","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Gori S, Faggiano P et al (2012) Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 23(12):3058\u20133063. https:\/\/doi.org\/10.1093\/annonc\/mds127","journal-title":"Ann Oncol"},{"issue":"24","key":"5178_CR14","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504\u20132512. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"5178_CR15","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/sj.bjc.6603340","volume":"95","author":"KF Fox","year":"2006","unstructured":"Fox KF (2006) The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy. Br J Cancer 95(10):1454. https:\/\/doi.org\/10.1038\/sj.bjc.6603340","journal-title":"Br J Cancer"},{"issue":"1","key":"5178_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10(1):337. https:\/\/doi.org\/10.1186\/1471-2407-10-337","journal-title":"BMC Cancer"},{"issue":"11","key":"5178_CR17","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin. Cancer 97(11):2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"25","key":"5178_CR18","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808\u20133815. https:\/\/doi.org\/10.1200\/JCO.2006.10.4976","journal-title":"J Clin Oncol"},{"issue":"6","key":"5178_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM197902083000603","volume":"300","author":"J Alexander","year":"1979","unstructured":"Alexander J, Dainiak N, Berger HJ et al (1979) Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300(6):278\u2013283. https:\/\/doi.org\/10.1056\/NEJM197902083000603","journal-title":"N Engl J Med"},{"issue":"5","key":"5178_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/1097-0142(19800901)46:5<1109::AID-CNCR2820460506>3.0.CO;2-B","volume":"46","author":"JL Ritchie","year":"1980","unstructured":"Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW (1980) Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46(5):1109\u20131116. https:\/\/doi.org\/10.1002\/1097-0142(19800901)46:5%3C1109::AID-CNCR2820460506%3E3.0.CO;2-B .","journal-title":"Cancer"},{"key":"5178_CR21","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v021.i03","author":"D Zamar","year":"2007","unstructured":"Zamar D, McNeney B, Graham J (2007) elrm: software implementing exact-like inference for logistic regression models. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v021.i03","journal-title":"J Stat Softw"},{"issue":"1","key":"5178_CR22","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","volume":"127","author":"AS Go","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL et al (2013) Heart disease and stroke statistics\u20132013 update: a report from the American Heart Association. Circulation 127(1):e6\u2013e245. https:\/\/doi.org\/10.1161\/CIR.0b013e31828124ad","journal-title":"Circulation"},{"issue":"26","key":"5178_CR23","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","volume":"31","author":"SM Swain","year":"2013","unstructured":"Swain SM, Tang G, Geyer CE et al (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31(26):3197\u20133204. https:\/\/doi.org\/10.1200\/JCO.2012.48.1275","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"5178_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2016.34.15_suppl.1000","volume":"34","author":"JL Blum","year":"2016","unstructured":"Blum JL, Flynn PJ, Yothers G et al (2016) Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06\u2013090, NSABP B-46I\/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline\/taxane-based chemotherapy regimens (Tax. J Clin Oncol 34(15_suppl):1000. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.1000","journal-title":"J Clin Oncol"},{"issue":"10","key":"5178_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"Investigators* TS","year":"1992","unstructured":"Investigators* TS (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327(10):685\u2013691. https:\/\/doi.org\/10.1056\/NEJM199209033271003","journal-title":"N Engl J Med"},{"issue":"11","key":"5178_CR26","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","volume":"16","author":"M Ryberg","year":"1998","unstructured":"Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16(11):3502\u20133508. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3502","journal-title":"J Clin Oncol"},{"issue":"17","key":"5178_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJA Bowles","year":"2012","unstructured":"Bowles EJA, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. JNCI J Natl Cancer Inst 104(17):1293\u20131305. https:\/\/doi.org\/10.1093\/jnci\/djs317","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"11","key":"5178_CR28","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","volume":"113","author":"WC Levy","year":"2006","unstructured":"Levy WC, Mozaffarian D, Linker DT et al (2006) The seattle heart failure model: prediction of survival in heart failure. Circulation 113(11):1424\u20131433. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.584102","journal-title":"Circulation"},{"key":"5178_CR29","unstructured":"Cancer Statistics SEER Review 1975\u20132005\u2014Previous version\u2014SEER cancer statistics. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2005\/ . Accessed December 25, 2017"},{"key":"5178_CR30","unstructured":"Arias E, Curtin LR, Wei R, Anderson RN (2008) National vital statistics reports 57(1). https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr57\/nvsr57_01.pdf . Accessed 25 Dec 2017"},{"issue":"10","key":"5178_CR31","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1200\/JCO.1999.17.10.3082","volume":"17","author":"PP Leung","year":"1999","unstructured":"Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G (1999) Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 17(10):3082\u20133090. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3082","journal-title":"J Clin Oncol"},{"issue":"9","key":"5178_CR32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.18553\/jmcp.2008.14.9.844","volume":"14","author":"GB Kruse","year":"2008","unstructured":"Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S (2008) Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm 14(9):844\u2013857. https:\/\/doi.org\/10.18553\/jmcp.2008.14.9.844","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"5178_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1023\/B:BREA.0000010689.55559.06","volume":"83","author":"S Rao","year":"2004","unstructured":"Rao S, Kubisiak J, Gilden D (2004) Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 83(1):25\u201332. https:\/\/doi.org\/10.1023\/B:BREA.0000010689.55559.06","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5178_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/CIRCOUTCOMES.110.957225","volume":"4","author":"SM Dunlay","year":"2011","unstructured":"Dunlay SM, Shah ND, Shi Q et al (2011) Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes 4(1):68\u201375. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.957225","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7 Suppl 1","key":"5178_CR35","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/MLR.0b013e3181a2d847","volume":"47","author":"WE Barlow","year":"2009","unstructured":"Barlow WE (2009) Overview of methods to estimate the medical costs of cancer. Med Care 47(7 Suppl 1):S33\u2013S36. https:\/\/doi.org\/10.1097\/MLR.0b013e3181a2d847","journal-title":"Med Care"},{"issue":"6","key":"5178_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1525-1497.2005.0116.x","volume":"20","author":"JS Mandelblatt","year":"2005","unstructured":"Mandelblatt JS, Schechter CB, Yabroff KR et al (2005) Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med 20(6):487\u2013496. https:\/\/doi.org\/10.1111\/j.1525-1497.2005.0116.x","journal-title":"J Gen Intern Med"},{"issue":"10","key":"5178_CR37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7326\/M13-2498","volume":"160","author":"FL Wong","year":"2014","unstructured":"Wong FL, Bhatia S, Landier W et al (2014) Cost-effectiveness of the children\u2019s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 160(10):672. https:\/\/doi.org\/10.7326\/M13-2498","journal-title":"Ann Intern Med"},{"issue":"3","key":"5178_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1148\/radiol.09091086","volume":"254","author":"JM Lee","year":"2010","unstructured":"Lee JM, McMahon PM, Kong CY et al (2010) Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 254(3):793\u2013800. https:\/\/doi.org\/10.1148\/radiol.09091086","journal-title":"Radiology"},{"issue":"8","key":"5178_CR39","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.amjcard.2012.05.059","volume":"110","author":"SD Reed","year":"2012","unstructured":"Reed SD, Li Y, Dunlap ME et al (2012) In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol 110(8):1150\u20131155. https:\/\/doi.org\/10.1016\/J.AMJCARD.2012.05.059","journal-title":"Am J Cardiol"},{"key":"5178_CR40","doi-asserted-by":"crossref","unstructured":"Levinsky NG, Yu W, Ash A et al (2001) Influence of age on medicare expenditures and medical care in the last year of life. JAMA 286(11):1349\u20131355. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11560540 . Accessed 25 Dec 2017","DOI":"10.1001\/jama.286.11.1349"},{"key":"5178_CR41","doi-asserted-by":"crossref","unstructured":"Folland S, Goodman AC, Stano M. The Economics of Health and Health Care. http:\/\/www.ssu.ac.ir\/cms\/fileadmin\/user_upload\/Daneshkadaha\/dbehdasht\/modiryat_khatamat_behdashti\/kotob_farsi\/The_economics_of_health_and_health_care-_Sherman_Folland.pdf . Accessed 25 Dec 2017","DOI":"10.4324\/9781315103488"},{"issue":"11","key":"5178_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/jnci\/djj210","volume":"98","author":"NK Stout","year":"2006","unstructured":"Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG (2006) Retrospective cost-effectiveness analysis of screening mammography. JNCI J Natl Cancer Inst 98(11):774\u2013782. https:\/\/doi.org\/10.1093\/jnci\/djj210","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"5178_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R et al (1993) The Beaver dam health outcomes study. Med Decis Mak 13(2):89\u2013102. https:\/\/doi.org\/10.1177\/0272989X9301300202","journal-title":"Med Decis Mak"},{"issue":"5","key":"5178_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jval.2016.02.010","volume":"19","author":"S-Y Wang","year":"2016","unstructured":"Wang S-Y, Hsu SH, Gross CP et al (2016) Association between time since cancer diagnosis and health-related quality of life: a population-level analysis. Value Health 19(5):631\u2013638. https:\/\/doi.org\/10.1016\/j.jval.2016.02.010","journal-title":"Value Health"},{"key":"5178_CR45","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR (1996) Cost-effectiveness in health and medicine. Oxford University Press, Oxford"},{"issue":"4","key":"5178_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/027298902400448867","volume":"22","author":"AH Briggs","year":"2002","unstructured":"Briggs AH, Goeree R, Blackhouse G, O\u2019Brien BJ (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Mak 22(4):290\u2013308. https:\/\/doi.org\/10.1177\/0272989X0202200408","journal-title":"Med Decis Mak"},{"issue":"1","key":"5178_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12885-014-1004-0","volume":"15","author":"A Mina","year":"2015","unstructured":"Mina A, Rafei H, Khalil M, Hassoun Y, Nasser Z, Tfayli A (2015) Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients. BMC Cancer 15(1):10. https:\/\/doi.org\/10.1186\/s12885-014-1004-0","journal-title":"BMC Cancer"},{"issue":"6","key":"5178_CR48","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1634\/theoncologist.2015-0449","volume":"21","author":"SR Truong","year":"2016","unstructured":"Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH (2016) Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment. Oncologist 21(6):666\u2013670. https:\/\/doi.org\/10.1634\/theoncologist.2015-0449","journal-title":"Oncologist"},{"issue":"9","key":"5178_CR49","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1161\/01.CIR.0000073597.57414.A9","volume":"108","author":"MD Cheitlin","year":"2003","unstructured":"Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC\/AHA\/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108(9):1146\u20131162. https:\/\/doi.org\/10.1161\/01.CIR.0000073597.57414.A9","journal-title":"Circulation"},{"key":"5178_CR50","unstructured":"Klocke FJ, Baird MG, Lorell BH et al (2003) ACC\/AHA\/ASNC guidelines for the clinical use of cardiac radionuclide imaging\u2013executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 42(7):1318\u20131333. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14522503 . Accessed 25 Dec 2017"},{"key":"5178_CR51","unstructured":"Sabel MS, Levine EG, Hurd T et al (2001) Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition. Am J Clin Oncol 24(4):425\u2013428. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11474280 . Accessed 25 Dec 2017"},{"key":"5178_CR52","doi-asserted-by":"crossref","unstructured":"Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH (2001) Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol 23(7):420\u2013423. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11878575 . Accessed 25 Dec 2017","DOI":"10.1097\/00043426-200110000-00006"},{"issue":"1","key":"5178_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clbc.2011.07.006","volume":"12","author":"A Jeyakumar","year":"2012","unstructured":"Jeyakumar A, DiPenta J, Snow S et al (2012) Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. Clin Breast Cancer 12(1):4\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2011.07.006","journal-title":"Clin Breast Cancer"},{"key":"5178_CR54","unstructured":"van Royen N, Jaffe CC, Krumholz HM et al (1996) Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77(10):843\u2013850. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8623737 . Accessed 25 Dec 2017"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05178-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T07:06:58Z","timestamp":1721200018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05178-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["5178"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05178-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Maysa M. Abu-Khalaf MD: Received honorarium for a Consultant\/Advisory role from AstraZeneca, Immunomedics, PUMA, Biothera and Agendia. Received a research grant from Novartis for an investigator-initiated clinical trial. Christos Hatzis PhD: Received remuneration from Bristol-Myers Squibb. Lajos Pusztai MD DPhil: Received honorarium for a Consultant\/Advisory role from Merck, Astrazeneca, Novartis, Seattle Genetics, Pfizer, and Almac: received research funding from Merck, AstraZeneca, and Seattle Genetics. Cary P. Gross MD: Received remuneration\/Travel funding from Flatiron Health and received research funding from Johnson &Johnson and NCCN\/Pfizer. Raymond Russell MD, PhD: Spouse employed by ResTORbio. Spouse receives stock options from ResTORbio. All other authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by institutional review board for this retrospective review study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}